

AMENDMENT OF CLAIMS:

Please amend the claims as follows:

1. (currently amended) A polymeric composition having improved capability to solubilize a drug in a hydrophilic environment, comprising: a biodegradable ABA-type, or BAB-type block copolymer, comprising:

i) 50.1 to 65% by weight of a biodegradable, hydrophobic A polymer block comprising a biodegradable polyester, and

ii) 35 to 49.9% by weight of a hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the block copolymer has a weight averaged molecular weight of between 1500 to 3099 Daltons,

wherein the polymeric composition has a block copolymer concentration in the range of about 5 to 40%, and said polymeric composition when formed as an aqueous polymer solution, is a free flowing liquid at body temperature remains a free flowing liquid upon parenteral administration.

2. (previously presented) The polymeric composition according to claim 1 wherein the biodegradable polyester of the hydrophobic A polymer block is synthesized from monomers including D, L-lactide, D-lactide, L-lactide, D, L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, ε-caprolactone, ε-hydroxy hexanoic acid, or copolymers thereof.

3. (original) The polymeric composition according to claim 1 wherein the A polymer block comprises between about 20 to 100 mole percent lactide or lactic acid, and between about 0 to 80 mole percent glycolide or glycolic acid.

4. (currently amended) A biodegradable polymeric drug delivery composition capable of solubilizing a drug in a hydrophilic environment to form a solution, comprising:

(a) an effective amount of a drug; and

(b) a biodegradable ABA-type, or BAB-type block copolymer comprising:

i) 50.1 to 65% by weight of a biodegradable, hydrophobic A polymer block comprising a biodegradable polyester, and

ii) 35 to 49.9% by weight of a hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the block copolymer has a weight-averaged molecular weight of between 1500 to 3099 Daltons,

wherein the polymeric composition has a block copolymer concentration in the range of about 5 to 40%, and said composition ~~forms a free flowing liquid at body temperatures in an aqueous environment~~ remains a free flowing liquid upon parenteral administration.

5. (previously presented) The polymeric drug delivery composition according to claim 4 wherein the biodegradable polyester of the hydrophobic A polymer block is synthesized from monomers including D, L-lactide, D-lactide, L-lactide, D, L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, ϵ -caprolactone, ϵ -hydroxy hexanoic acid, or copolymers thereof.

6. (original) The polymeric drug delivery composition according to claim 4 wherein the A polymer block comprises between about 20 to 100 mole percent lactide or lactic acid, and between about 0 to 80 mole percent glycolide or glycolic acid.

7. (original) The polymeric drug delivery composition according to claim 4 wherein the drug content is 10^{-6} to 100% of the total triblock copolymer weight.

8. (currently amended) A biodegradable polymer solution as a drug delivery vehicle capable of solubilizing a drug in a hydrophilic environment, comprising: a functional concentration of a biodegradable ABA-type, or BAB-type block copolymer and an aqueous solution, said block copolymer comprising:

i) 50.1 to 65% by weight of a biodegradable, hydrophobic A polymer block comprising a biodegradable polyester, and

ii) 35 to 49.9% by weight of a hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the block copolymer has a weight-averaged molecular weight of between 1500 to 3099 Daltons;

and wherein the polymeric composition has a block copolymer concentration in the range of about 5 to 40%, and said polymer solution ~~is a free flowing liquid at body temperatures~~ remains a free flowing liquid upon parenteral administration.

9. (currently amended) The polymeric solution according to claim 8, wherein said ~~functional block copolymer~~ concentration of said copolymer is between about ~~1 to 50%~~ 10 to 30% by weight of said polymer solution.

10. (previously presented) The polymeric composition according to claim 8 wherein the biodegradable polyester of the hydrophobic A polymer block is synthesized from monomers including D, L-lactide, D-lactide, L-lactide, D, L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, ε-caprolactone, ε-hydroxy hexanoic acid, or copolymers thereof.

11. (original) The polymeric composition according to claim 8 wherein the A polymer block comprises between about 20 to 100 mole percent lactide or lactic acid, and between about 0 to 80 mole percent glycolide or glycolic acid.

12. (currently amended) A biodegradable drug solution comprising:

(a) an effective amount of a drug solubilized in a polymer solution comprising;

(1) a functional concentration of a biodegradable ABA-type, or BAB-type block copolymer capable of solubilizing said drug in a hydrophilic environment, comprising:

i) 50.1 to 65% by weight of a biodegradable, hydrophobic A polymer block comprising a biodegradable polyester, and

ii) 35 to 49.9% by weight of a hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the tri-block copolymer has a weight-averaged molecular weight of between 1500 to 3099 Daltons; and

(2) an aqueous solution, wherein the polymeric composition has a block copolymer concentration in the range of about 5 to 40%, and said polymer solution ~~is a free flowing liquid at a body temperature~~ remains a free flowing liquid upon parenteral administration.

13. (original) The biodegradable aqueous polymeric drug solution according to claim 12 further comprising excipients, additives, buffers, osmotic pressure adjusting agents, antioxidants, preservatives, drug stabilizing agents or equivalents thereof.

14. (currently amended) The biodegradable aqueous polymeric drug solution according to claim 12, wherein said ~~functional- block copolymer~~ concentration ~~of said copolymer~~ is between about ~~1 to 50%~~ 10 to 30% by weight of said polymeric solution.

15. (original) The biodegradable aqueous polymeric drug solution according to claim 12 wherein the drug content is 10^{-6} to 100% of the total triblock copolymer weight.

16. (previously presented) The biodegradable aqueous polymeric drug solution according to claim 12 wherein the biodegradable polyester of the hydrophobic A polymer block is synthesized from monomers including D, L-lactide, D-lactide, L-lactide, D, L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, ϵ -caprolactone, ϵ -hydroxy hexanoic acid, or copolymers thereof.

17. (original) The biodegradable aqueous polymeric drug solution according to claim 12 wherein the A-block comprises between about 20 to 100 mole percent lactide or lactic acid and between about 0 to 80 mole percent glycolide or glycolic acid.

18. (currently amended) A method for administering a drug to a warm blooded animal, comprising

(1) providing a biodegradable polymeric drug delivery composition comprising:

(a) an effective amount of a drug; and

(b) a biodegradable ABA-type, or BAB-type block copolymer comprising:

i) 50.1 to 65% by weight of a biodegradable, hydrophobic A polymer block comprising a biodegradable polyester, and

ii) 35 to 49.9% by weight of a hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the block copolymer has a weight-averaged molecular weight of between 1500 to 3099 Daltons,

wherein the polymeric composition has a block copolymer concentration in the range of about 5 to 40%, and said polymeric composition ~~forms a free flowing liquid at body temperature in an aqueous environment~~ remains a free flowing liquid upon parenteral administration, and

(2) administering said composition to said warm blooded animal.

19. (previously presented) The method according to claim 18 wherein the biodegradable polyester of the hydrophobic A polymer block is synthesized from monomers including D, L-lactide, D-lactide, L-lactide, D, L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, ϵ -caprolactone, ϵ -hydroxy hexanoic acid, or copolymers thereof.

20. (original) The method according to claim 18 wherein the A polymer block comprises between about 20 to 100 mole percent lactide or lactic acid, and between about 0 to 80 mole percent glycolide or glycolic acid.

21. (original) The method according to claim 18 wherein the drug content is 10^{-6} to 100% of the total triblock copolymer weight.

22. (original) The method according to claim 18 wherein said administration is by parenteral, ocular, topical, inhalation, transdermal, vaginal, buccal, transmucosal, transurethral, rectal, nasal, oral, peroral, pulmonary or aural means.

23. (currently amended) A method for administering a drug to a warm blooded animal, comprising

(1) providing a biodegradable polymeric drug solution comprising an effective amount of a drug solubilized in a polymer solution comprising;

(a) a functional concentration of a biodegradable ABA-type, or BAB-type block copolymer capable of solubilizing said drug in a hydrophilic environment, comprising:

i) 50.1 to 65% by weight of a biodegradable, hydrophobic A polymer block comprising a biodegradable polyester, and

ii) 35 to 49.9% by weight of a hydrophilic B polymer block comprising a polyethylene glycol(PEG), and wherein the tri-block copolymer has a weight-averaged molecular weight of between 1500 to 3099 Daltons; and

(b) an aqueous solution, wherein the polymeric solution has a block copolymer concentration in the range of about 5 to 40%, and said polymer solution ~~is a free flowing liquid at body temperatures~~ remains a free flowing liquid upon parenteral administration, and;

(2) administering said drug solution to said warm blooded animal.

24. (currently amended) The method according to claim 23, wherein the ~~functional- block~~
copolymer concentration of said ~~copolymer~~ is between about ~~1 to 50%~~ 10 to 30% by weight of
said polymer solution.

25. (previously presented) The method according to claim 23 wherein the biodegradable
polyester of the hydrophobic A polymer block is synthesized from monomers including D, L-
lactide, D-lactide, L-lactide, D, L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic
acid, ϵ -caprolactone, ϵ -hydroxy hexanoic acid, or copolymers thereof.

26. (original) The method according to claim 23 wherein the A-block comprises between about
20 to 100 mole percent lactide or lactic acid and between about 0 to 80 mole percent glycolide or
glycolic acid.

27. (original) The method according to claim 23 wherein the drug content is 10^{-6} to 100% of the
total triblock copolymer weight.

28. (original) The method according to claim 23 wherein said administration is by intramuscular,
intraperitoneal, intra-abdominal, subcutaneous, intrathecal, intrapleural, intravenous or
intraarterial means.

29. (currently amended) A method for enhancing the solubility of a drug, comprising
1) preparing a polymeric composition comprising a functional concentration of a biodegradable
ABA-type, or BAB-type block copolymer, comprising:

i) 50.1 to 65% by weight of a biodegradable, hydrophobic A polymer block comprising a
biodegradable polyester, and

ii) 35 to 49.9% by weight of a hydrophilic B polymer block comprising a polyethylene
glycol (PEG), and wherein the block copolymer has a weight averaged molecular weight of
between 1500 to 3099 Daltons,

2) admixing the polymeric composition with a drug; and

3) admixing the drug containing polymeric composition with an aqueous solution to obtain a drug solution that has a block copolymer concentration in the range of about 5 to 40%, and that remains a free flowing liquid at body temperatures remains a free flowing liquid upon parenteral administration.

30. (currently amended) The method according to claim 23, wherein the functional block copolymer concentration of said copolymer is between about ~~1 to 50%~~ 10 to 30% by weight of said polymer solution.

31. (previously presented) The method according to claim 29 wherein the biodegradable polyester of the hydrophobic A polymer block is synthesized from monomers including D, L-lactide, D-lactide, L-lactide, D, L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, ϵ -caprolactone, ϵ -hydroxy hexanoic acid, or copolymers thereof.

32. (original) The method according to claim 31 wherein the A-block comprises between about 20 to 100 mole percent lactide or lactic acid and between about 0 to 80 mole percent glycolide or glycolic acid.

33. (original) The method according to claim 29 wherein the drug content is 10^{-6} to 100% of the total triblock copolymer weight.

34. (currently amended) A method for enhancing the solubility of a drug, comprising
1) preparing a polymeric composition comprising a functional concentration of a biodegradable ABA-type, or BAB-type block copolymer, comprising:

i) 50.1 to 65% by weight of a biodegradable, hydrophobic A polymer block comprising a biodegradable polyester, and

ii) 35 to 49.9% by weight of a hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the block copolymer has a weight averaged molecular weight of between 1500 to 3099 Daltons,

2) admixing said composition with an aqueous solution to form a polymeric solution that has a block copolymer concentration in the range of about 5 to 40%, and that ~~remains a free flowing~~

~~liquid at body temperatures~~ remains a free flowing liquid upon parenteral administration, and

3) admixing said polymer solution with a drug to form a drug solution.

35. (currently amended) The method according to claim 34, wherein the ~~functional block copolymer~~ concentration of said copolymer is between about ~~1 to 50%~~ 10 to 30% by weight of said polymer solution.

36. (previously presented) The method according to claim 34 wherein the biodegradable polyester of the hydrophobic A polymer block is synthesized from monomers including D, L-lactide, D-lactide, L-lactide, D, L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, ϵ -caprolactone, ϵ -hydroxy hexanoic acid, or copolymers thereof.

37. (original) The method according to claim 34 wherein the A-block comprises between about 20 to 100 mole percent lactide or lactic acid and between about 0 to 80 mole percent glycolide or glycolic acid.

38. (original) The method according to claim 34 wherein the drug content is 10^{-6} to 100% of the total triblock copolymer weight.

39. (currently amended) A method for enhancing the solubility of a drug, comprising

1) preparing a polymeric composition comprising a functional concentration of a biodegradable ABA-type, or BAB-type block copolymer, comprising:

i) 50.1 to 65% by weight of a biodegradable, hydrophobic A polymer block comprising a biodegradable polyester, and

ii) 35 to 49.9% by weight of a hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the block copolymer has a weight averaged molecular weight of between 1500 to 3099 Daltons,

2) admixing a drug with an aqueous solution to form a drug-aqueous solution mixture, and

3) admixing said polymer composition with said drug-aqueous solution mixture to form a drug polymeric solution that has a block copolymer concentration in the range of about 5 to 40%, and that ~~remains as a free flowing liquid at a body temperature~~ remains a free flowing liquid upon

parenteral administration.

40. (currently amended) The method according to claim 39, wherein the ~~functional block~~ copolymer concentration of ~~said copolymer~~ is between about ~~1 to 50%~~ 10 to 30% by weight of said polymer solution.

41. (previously presented) The method according to claim 39 wherein the biodegradable polyester of the hydrophobic A polymer block is synthesized from monomers including D, L-lactide, D-lactide, L-lactide, D, L-lactic acid, D-lactic acid, L-lactic acid, glycolide, glycolic acid, ϵ -caprolactone, ϵ -hydroxy hexanoic acid, or copolymers thereof.

42. (previously presented) The method according to claim 39 wherein the A-block comprises of between about 20 to 100 mole percent lactide or lactic acid and between about 0 to 80 mole percent glycolide or glycolic acid.

43. (previously presented) The method according to claim 39 wherein the drug content is 10^{-6} to 100% of the total tri block copolymer weight.

44. (new) A polymeric composition having improved capability to solubilize a drug in a hydrophilic environment, comprising: a biodegradable ABA-type, or BAB-type block copolymer, comprising:

- i) about 52 % by weight of a biodegradable, hydrophobic A polymer block comprising a biodegradable polyester, and
- ii) about 48 % by weight of a hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the block copolymer has a weight averaged molecular weight of between 1500 to 3099 Daltons, wherein the polymeric composition has a block copolymer concentration in the range of about 5 to 40%.

45. (new) The polymeric composition according to claim 44, wherein the weight average molecular weight is 3099 Daltons.

46. (new) A biodegradable polymeric drug delivery composition capable of solubilizing a drug in a hydrophilic environment to form a solution, comprising:

(a) an effective amount of a drug; and

(b) a biodegradable ABA-type, or BAB-type block copolymer comprising:

i) about 52 % by weight of a biodegradable, hydrophobic A polymer block comprising a biodegradable polyester, and

ii) about 48 % by weight of a hydrophilic B polymer block comprising a polyethylene glycol (PEG), and wherein the block copolymer has a weight-averaged molecular weight of between 1500 to 3099 Daltons, wherein the polymeric composition has a block copolymer concentration in the range of about 5 to 40%.

47. (new) The biodegradable polymeric drug delivery composition according to claim 46, wherein the weight average molecular weight is 3099 Daltons.